Nutrien Ltd. NTR

Healthcare SIC 2870 - Agricultural Chemicals NAICS Manufacturing › Chemical Manufacturing › Pesticide, Fertilizer, and Other Agricultural Chemical Manufacturing › Fertilizer and Compost Manufacturing derived NYSE

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating income $3.74B$1.86B$2.75B$10.81B$4.78B$902.0M$1.86B$414.0M$209.0M—
Net income $2.30B$700.0M$1.28B$7.69B$3.18B$459.0M$992.0M$3.57B$327.0M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets $52.30B$51.84B$52.75B$54.59B$49.95B$47.19B$46.80B$45.50B$17.00B—
Total equity $25.36B$24.44B$25.20B$25.86B$23.70B$22.40B$22.91B$24.43B$8.30B$8.20B

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-081326.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
  • Long-term debt
Revenue, Gross profit, Net income, Long-term debt by fiscal year, in US dollars The same figures are in the table below this chart. 0 2B 4B 6B 8B Net income, FY2017: 327M Net income, FY2018: 3.6B Net income, FY2019: 992M Net income, FY2020: 459M Net income, FY2021: 3.2B Net income, FY2022: 7.7B Net income, FY2023: 1.3B Net income, FY2024: 700M Net income, FY2025: 2.3B FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — — — — — — — — —
Gross profit — — — — — — — — — —
Net income — $327.0M $3.57B $992.0M $459.0M $3.18B $7.69B $1.28B $700.0M $2.30B
Long-term debt — — — — — — — — — —

Others in SIC 2870

TickerCompanyMarket capP/ERevenue growth
CF CF Industries Holdings, Inc. $20.18B 14.9x 19.3%
MOS MOSAIC CO $8.22B 15.2x 8.4%
SMG SCOTTS MIRACLE-GRO CO $3.46B 24.1x -3.9%
UAN CVR PARTNERS, LP $1.38B 14.0x 15.4%
CBUS Cibus, Inc. $122.0M — -14.6%
AVD AMERICAN VANGUARD CORP $68.7M — -5.9%
SNES SenesTech, Inc. $5.4M — 19.6%
EVGN Evogene Ltd. — — -30.9%